Champions Oncology (CSBR) Change in Accured Expenses (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly Change in Accured Expenses of $1.2 million in Q1 2026, up 198.2% quarter-over-quarter from $388000.0 in Q4 2025, and up 3515.62% on a YoY basis from $32000.0 in Q1 2025.
Champions Oncology (CSBR) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Champions Oncology's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $1.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 3515.62% year-over-year to $1.2 million; the TTM figure through Jan 2026 stood at $1.1 million (up 761.96% YoY), while the FY2025 annual figure was $395000.0, up 462.39% from the prior year.
- Change in Accured Expenses was $1.2 million for Q1 2026 at Champions Oncology, up from $388000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.2 million in Q1 2026 to a low of -$755000.0 in Q3 2025.
- Historically, Change in Accured Expenses has averaged $84352.9 across 5 years, with a median of $137000.0 in 2024.
- The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses tumbled 3140.0% in 2022, then jumped 3515.62% in 2026.
- A 5-year view of Change in Accured Expenses shows it stood at -$287000.0 in 2022, then surged by 76.66% to -$67000.0 in 2023, then soared by 304.48% to $137000.0 in 2024, then surged by 183.21% to $388000.0 in 2025, then jumped by 198.2% to $1.2 million in 2026.
- The last three Change in Accured Expenses figures came in at $1.2 million (Q1 2026), $388000.0 (Q4 2025), and -$755000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 931,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 1.16 Mn |
| Jan 31, 2026 | 1.16 Mn |
| Oct 31, 2025 | 388,000.00 |
| Oct 31, 2025 | 388,000.00 |
| Jul 31, 2025 | -755,000.00 |
| Jul 31, 2025 | -755,000.00 |
| Apr 30, 2025 | 289,000.00 |
| Apr 30, 2025 | 289,000.00 |
| Jan 31, 2025 | 32,000.00 |
| Jan 31, 2025 | 32,000.00 |
| Oct 31, 2024 | 137,000.00 |
| Oct 31, 2024 | 137,000.00 |
| Jul 31, 2024 | -63,000.00 |
| Jul 31, 2024 | -63,000.00 |
| Apr 30, 2024 | -269,000.00 |
| Apr 30, 2024 | -269,000.00 |
| Jan 31, 2024 | 405,000.00 |
| Jan 31, 2024 | 405,000.00 |
| Oct 31, 2023 | -67,000.00 |
| Oct 31, 2023 | -67,000.00 |